BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-386@pharmaconomics
DTSTAMP:20260707T034512Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AGIO Phase 2 — tebapivat (estimated date)
DESCRIPTION:Phase 2 trial results for tebapivat in Sickle Cell Disease are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000071/agio-42926xfyxex991earning.htm\n\nTrack it: https://www.pharmaconomics.com/e/386
URL:https://www.pharmaconomics.com/e/386
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AGIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR